"Pharmaceutical Speed Reader" FDA released the new crown vaccine listing standard Junshi issue price set at 55.5 yuan.

the price of the new crown virus detection reagent linked; Junshi biological issue price is set at 55.5 yuan; Inovio new crown vaccine phase 1 clinical immune response rate of 94%; The drug, car-t-T, is on the market, and the FDA has issued a new standard for the listing of a new crown vaccineOn June 30, the Shanghai Municipal Health Insurance Bureau and the Health and Health Commission issued a notice on reducing the price of the city's new coronavirus nucleic acid testing and antibody testing project and including in the scope of medical insurance paymentIt is pointed out that the new crown virus detection reagent production/total enterprises can fill in the "sunshine platform" certificate system product base information and price information of foreign provinces and cities (referring to Beijing, Tianjin, Jiangsu, Zhejiang, Guangdong, Chongqing, Anhui, Fujian, Jiangxi, Shandong, Henan, Hebei, Liaoning, Hubei, Hunan 15 provinces)(Shanghai Medical Insurance Bureau, etc.)Liaoning Province drug and medical supplies centralized procurement network on June 29 issued "on the medical supplies with the same price results to implement the promotion of comprehensive medical supplies work notice", involving 38,658 kinds of suppliesNotice requirements, the province's municipalities unified on July 1 at 0:00 to implement medical supplies with the same price results, and the medical and health institutions within a month to complete the original product inventory digestion and other work(Liaoning Province Drug and Medical Supplies Centralized Procurement Network)June 30, Junshi Bio issued an initial public offering of shares and listed on the board of the announcement, according to the preliminary results of the inquiry, determined the issue price of 55.50 yuan / share, the corresponding "market value / research and development costs" multiple of 51.11 times, the total market value after the issue of 48.356 billion yuanJunshi Bio H shares closed at about 52.03 yuan per share on June 29, and the offering price of the COMPANY's IPO was about 6.67 percent premium to the H-share priceJunshi Bio will be available online and offline on July 2(Shanghai Securities News)Baiji Shenzhou announced that angarve ® (Ground supta anti-injection) for the treatment of osteocyte tumor sesame has been officially commercialized in ChinaThis is the first drug produced by Anjin to be officially launched commercially available in China following the global oncology strategic cooperation reached by Baiji Shenzhou and Anjin in January 2020On June 30,, U.Sbiotech company Inovio disclosed preliminary findings of its experimental new coronavaccinee, INO-4800, announcing that 94 percent of subjects in Phase 1 clinical trials showed an overall immune response(Sina Pharmaceutical News) Alnylam has released a long-term, open-label extension of Givlaari that promises to dispel concerns about the safety of long-term drug use The data showed that during the one-year treatment period, Givlaari showed consistent efficacy in reducing the number of seizures in AHP patients, and there was evidence that the efficacy increased over time (Sina Pharmaceutical News) Seattle Genetics has announced that it and Genmab jointly developed an innovative antibody conjugate drug (ADC) tisotumab vedotin, in a potentially registered phase 2 clinical trial called innovaTV204 In the treatment of patients with recurrent or metastatic cervical cancer, the objective remission rate (ORR) confirmed by the Independent Center review was 24% (95% CI: 15.9%-33.3%) and the median duration of the remission (DOR) was 8.3 months (Pharmaceutical Mingcon) today Akero announced the results of its FGF21 derivative efruxifermin (aka AKR-001) in a clinical phase called Balanced II Forty-eight percent of the patients who used the 16-week dose of efruxifermin improved at least level 1 fibrosis, 28 percent improved level 2 fibrosis, and the placebo group had 0 (although only two had biopsy data) (U.S Traditional Chinese Medicine Source) drug Ming Juno june 30 submitted the Ruijilensay injection (tentative) listing application to be accepted by CDE, is the domestic after Fosun Kate Ijillon race, the second declared listing of CAR-T therapy (Pharma Rubik's Cube) June 30, Haizheng Pharmaceutical industry issued a notice that it received the State Drug Administration on the company's initiative to apply for the withdrawal of the application for registration of ilikitakang injection drug, "approval notice", the company on May 9, 2012 according to the original drug 6 categories to the Zhejiang Provincial Drug Administration to submit the registration application and received acceptance, up to now the company has invested in the product research and development project of about 301.17 million yuan (Minnet.com) Xianxian Pharmaceuticals issued a notice that recently received the State Drug Administration issued by the hydrochloric acid luopicainininin injection consistency evaluation acceptance notice Minnet data show that in 2019 in China's public medical institutions terminal Luobiain sales have exceeded 1.1 billion, currently only Shi shi four drugs, Shandong Huaxin two reviews On June 30, , the FDA's Center for Biological Product Evaluation and Research (CBER) released the Industry Guide: CoVI9-19 Preventive Vaccine Development and Licensing document In the guidelines, CBER shared with the industry some considerations for COVID-19 preventive vaccines in CMC (chemistry, production and quality control), non-clinical data, clinical trials, post-market safety evaluation, etc The most central point is that the FDA requires the listed COVID-19 preventive vaccine to be at least 50 percent more effective at protecting than a placebo (Pharma Rubik's Cube) Merck and Pfizer jointly announced that the U.S FDA has approved the PD-L1 antibody Bavencio (avelumab) supplementary biologics licensing application (sBLA) for first-line maintenance treatment for patients with locally advanced or metastatic urethra skin cancer (UC) who have not progressed after receiving platinum-containing chemotherapy This is the first first first-line immunotherapy to provide significant total life improvement for this patient population in Phase 3 clinical trials, the press release said Ultragenyx Pharmaceuticals, , announced that the U.S FDA has approved Dojolvi (triheptanoin, triamcinolone) as a source of calories and fatty acids for the treatment of long-chain fatty acid oxidation disorder (LC-FAOD) pediatrics and adult patients identified by molecular diagnosis LC-FAOD is a rare group of life-threatening genetic disorders in which the patient's body is unable to convert long-chain fatty acids into energy The European Commission has approved its Hedgehog pathway inhibitor Daurismo (glasdegib), a low-dose chemotherapy drug, for use in newly diagnosed (new or secondary) patients with acute myeloid leukemia who are not suitable for standard chemotherapy, Pfizer has announced (Sina Pharmaceutical News) AstraZeneca recently announced that its target anti-cancer drug Koselugo (selumetinib) in Japan has been awarded orphan drug eligibility for the treatment of neurofibromatosis type 1 (Biovalley) Ono Pharmaceuticals recently announced that Japan's Ministry of Health and Labour has approved Ongentys (opicapone) 25mg tablet, a new, daily, oral selective catashile-oxygen-methyl transferase inhibitor, combined with lvodoba-kabidoba or levodobarba-hydrochloride, for use in adult patients with Parkinson's disease, to improve end-of-race fluctuations (BioValley) Transingroup Group announced that its subsidiary, Mybos Bio Independent lying with Claudin 18.2 (CLDN18.2) humanized monoclonal antibody drug TST001 in the United States, the first phase I clinical study has successfully completed the first patient-to-drug (A.S.C.) Carmine Therapeutics (Boyu Biology) announced a research cooperation agreement with Takeda to identify, develop and commercially promote thetherapy for two rare diseases using Carmine Therapeutics' REGENT ™ technology(based on red blood cell exfoliasis) (Pharma Rubik's Cube)